Marc Beer raises $42 million with new healthcare products

Marc Beer, Co-Founder, Chairman & CEO of Renovia Inc., has received necessary funding to carry out his ultimate mission. Beer and his team of healthcare professionals have put $42 million towards products designed for over 250 million women worldwide. Beer’s former 25 years of experience in developing and commercializing biotechnology, pharmaceuticals, devices and diagnostics, has more than qualified him to complete this task of developing therapeutic and diagnostic products. Marc Beer is the Founding Chairman of the Board for the compensating committee of Good Start Genetics Inc. and Chairman of the Board of the audit committee of Minerva Neurosciences Inc. He also served at OvaScience (Nasdaq: OVAS) as a strategic consultant and as Vice President of Global Marketing at Genzyme. He has spent many years with Genzyme, where he was responsible for several products being launched commercially addressing rare disease populations on a global scale. The new medtech company, Renovia Inc. is based in Boston and was started in August 2016. Beer’s founding partners for this company include Ramon Iglesias, MD and Yolanda Lorie. He also works closely with Renovia’s leaders William Dull, Chief Commercial Officer, Dr. Samantha Pulliam, MD, Chief Medical Officer, Jose Bohorquez, PhD, Chief Scientific Officer and Jessica McKinney, PT, MS, CMPT, Vice President of Medical Affairs and Clinical Advocacy.

 

Started for women who have been diagnosed with pelvic floor disorders, Renovia Inc. has developed many new treatment options for many different things relating to this very common and well known disorder. Recently receiving FDA approval, their very first product Leva will also soon be made as a new generation device. The funding the company received will be used in developing and testing four more products available from their company. Renovia Inc. and it’s investors are excited to make such a large impact on the lives of so many women. They also plan for these developments to ultimately help with lowering the costs of long term healthcare. Beer said, “We are thrilled to have the support of this group of leading healthcare investors who share our vision to better diagnose, treat and improve the lives of millions of women affected by pelvic floor disorders.” Learn more: https://www1.salary.com/Marc-Beer-Salary-Bonus-Stock-Options-for-AEGERION-PHARMACEUTICALS-INC.html